---
name: TRiCBIO
slug: tricbio
site: cro
website_domain: tricbio.com
summary: TRiCBIO provides human organoid research services for efficacy, safety, mechanism and immune-context studies using PDO 2.0 and ALI platforms, supporting biopharma and CRO teams in candidate evaluation and translational research. Headquartered in Nanjing, China.
tagline: Human organoid research for efficacy, safety, mechanism and immune-context studies.
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: CN
tier2_domain_verified: false
updated_at: 2026-09-21T07:01:24.815Z
services_count: 8
modalities_count: 3
indications_count: 4
locations_count: 3
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# TRiCBIO

Human organoid research for efficacy, safety, mechanism and immune-context studies.

Listed on cro.directory.

## Summary

TRiCBIO provides human organoid research services for efficacy, safety, mechanism and immune-context studies using PDO 2.0 and ALI platforms, supporting biopharma and CRO teams in candidate evaluation and translational research. Headquartered in Nanjing, China.

## At a glance

- HQ country: CN

## Services

- Translational Research
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Target Identification & Validation
- Discovery Research
- Medicinal Chemistry
- Biomarker Assays
- Flow Cytometry Services

## Modalities

- Antibody-Drug Conjugate (ADC)
- Biologics (Monoclonal Antibodies)
- Biologics (Other)

## Indications

- Oncology
- Immunology
- Rare Disease
- Gastroenterology

## Locations

- Nanjing, Nanjing, China
- Shanghai, Shanghai, China
- Philadelphia, Philadelphia, Pennsylvania, United States

## Long description

## Overview

TRiCBIO is a contract research organization specializing in human organoid-based drug development services. The company designs and executes organoid studies across efficacy, safety, mechanism of action, and tumor-immune microenvironment research using proprietary PDO 2.0 and ALI (air-liquid interface) platforms.

## Core Capabilities

**Human Organoid Platforms:**
- PDO 2.0 / ALI: Retains tissue architecture and immune cells from source samples for tumor-microenvironment profiling and immunotherapy studies
- Patient-derived organoids (PDO 1.0 and PDO 2.0) for efficacy and mechanism studies
- Normal-tissue organoids (kidney, lung, stomach, liver) for safety assessment
- Disease models including IBD inflammation, ADPKD, and BBB co-culture systems

**Research Services:**
- **Discovery & Validation:** Target identification, functional genomics screening, gene library screening, target function verification, and biomarker discovery in human organoid models
- **Candidate Drug Evaluation:** Efficacy screening, dose-response studies, combination therapy assessment, and mechanism-of-action studies
- **Immunology & Oncology:** Tumor-immune organoid studies, immunotherapy evaluation, antibody/bispecific/TCE assessment, and ADC research with spatial distribution and bystander killing endpoints
- **Safety & Delivery:** Organ-specific toxicity assessment in normal-tissue organoids, multi-organ safety studies, barrier integrity evaluation, and drug transport characterization

**Integrated Readouts:**
- Histology (H&E, immunofluorescence, immunohistochemistry)
- Flow cytometry and TCR profiling
- Cytokine analysis
- Viability and barrier function assays
- Functional response measurements

## Scientific Foundation

The company's Chief Scientist co-developed ALI organoid technology, with peer-reviewed publications in Nature Medicine and Cell. Research spans target discovery, functional genomics, ALI organoid biology, tumor biology, and clinical pharmacology.

## Global Operations

- **Nanjing (China):** Core R&D center handling organoid cultivation, sample processing, and multi-dimensional assays
- **Shanghai (China):** Customer communication and regional collaboration for Chinese clients
- **Philadelphia (USA):** International customer support and project coordination

## Collaboration Models

Services available as contract research, model and product supply, custom development, or joint scientific collaboration, with flexible engagement based on project stage and client needs.

## Related companies

- [Beantown Biotech](/companies/beantownbiotech) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/beantownbiotech/tricbio)
- [Nexus BioQuest](/companies/nexus-bioquest) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/nexus-bioquest/tricbio)
- [Reaction Biology](/companies/reactionbiology) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/reactionbiology/tricbio)
- [BioDuro-Sundia](/companies/bioduro-sundia) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/bioduro-sundia/tricbio)
- [Confluence Discovery Technologies, Inc.](/companies/confluencediscovery) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/confluencediscovery/tricbio)
- [ChemPartner](/companies/chempartner) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/chempartner/tricbio)
- [Crown Bioscience](/companies/crownbio) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/crownbio/tricbio)
- [Oncodesign Services](/companies/oncodesign-services) (Translational Research, In Vitro Pharmacology) — [Compare](/compare/oncodesign-services/tricbio)

_Profile last updated: 2026-09-21T07:01:24.815Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.